iBio, AstralBio to Rapidly Develop Novel Antibodies for Obesity, Cardiometabolic Diseases

 – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –

– iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets –

– Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration –

– Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration –

iBio will host a webcasted conference call with an associated slide presentation today, March 27, at 8:30 a.m. EDT to discuss its collaboration with AstralBio.

The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. To participate in the conference call by telephone, please pre-register via this link to receive the dial-in number and your unique PIN.

https://www.globenewswire.com/news-release/2024/03/27/2853011/0/en/iBio-and-AstralBio-Announce-Transformative-AI-drug-discovery-Collaboration-to-Rapidly-Develop-Novel-Antibodies-for-Obesity-and-Cardiometabolic-Diseases.html